<i>CSMD1</i> Mutations Are Associated with Increased Mutational Burden, Favorable Prognosis, and Anti-Tumor Immunity in Gastric Cancer
Tumor mutational burden (TMB) is considered a potential biomarker for predicting the response and effect of immune checkpoint inhibitors (ICIs). To find specific gene mutations related to TMB and the prognosis of patients, the frequently mutated genes in gastric cancer patients from TCGA and ICGC we...
Guardado en:
Autores principales: | Taobi Huang, Yuan Liang, Huiyun Zhang, Xia Chen, Hui Wei, Weiming Sun, Yuping Wang |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
MDPI AG
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/548a190aea1142ddb5e1a057a692f337 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Association of CSMD1 with Tumor Mutation Burden and Other Clinical Outcomes in Gastric Cancer
por: Wang X, et al.
Publicado: (2021) -
CSMD3 is Associated with Tumor Mutation Burden and Immune Infiltration in Ovarian Cancer Patients
por: Lu N, et al.
Publicado: (2021) -
Prognostic Value of Tumor Mutational Burden Related to Immune Infiltration in Cervical Squamous Cell Carcinoma
por: Fang Wen, et al.
Publicado: (2021) -
CSMD1 Mutation Related to Immunity Can Be Used as a Marker to Evaluate the Clinical Therapeutic Effect and Prognosis of Patients with Esophageal Cancer
por: Fan X, et al.
Publicado: (2021) -
The Construction of a Prognostic Model Based on a Peptidyl Prolyl Cis–Trans Isomerase Gene Signature in Hepatocellular Carcinoma
por: Huadi Shi, et al.
Publicado: (2021)